Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Molecules ; 20(3): 4915-27, 2015 Mar 18.
Article in English | MEDLINE | ID: mdl-25793541

ABSTRACT

Varied pharmacological responses have been reported for mitragynine in the literature, but no supportive scientific explanations have been given for this. These studies have been undertaken without a sufficient understanding of the physicochemical properties of mitragynine. In this work a UV spectrophotometer approach and HPLC-UV method were employed to ascertain the physicochemical properties of mitragynine. The pKa of mitragynine measured by conventional UV (8.11 ± 0.11) was in agreement with the microplate reader determination (8.08 ± 0.04). Mitragynine is a lipophilic alkaloid, as indicated by a logP value of 1.73. Mitragynine had poor solubility in water and basic media, and conversely in acidic environments, but it is acid labile. In an in vitro dissolution the total drug release was higher for the simulated gastric fluid but was prolonged and incomplete for the simulated intestinal fluid. The hydrophobicity, poor water solubility, high variability of drug release in simulated biological fluids and acid degradable characteristics of mitragynine probably explain the large variability of its pharmacological responses reported in the literature. The determined physicochemical properties of mitragynine will provide a basis for developing a suitable formulation to further improve its solubility, stability and oral absorption for better assessment of this compound in preclinical studies.


Subject(s)
Mitragyna/chemistry , Secologanin Tryptamine Alkaloids/chemistry , Secologanin Tryptamine Alkaloids/isolation & purification , Chromatography, High Pressure Liquid/methods , Drug Evaluation, Preclinical , Plant Leaves/chemistry , Solubility , Spectrophotometry, Ultraviolet/methods
2.
Stroke ; 45(5): 1422-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24699052

ABSTRACT

BACKGROUND AND PURPOSE: Previous cell-based and animal studies showed mixed tocotrienols are neuroprotective, but the effect is yet to be proven in humans. Thus, the present study aimed to evaluate the protective activity of mixed tocotrienols in humans with white matter lesions (WMLs). WMLs are regarded as manifestations of cerebral small vessel disease, reflecting varying degrees of neurodegeneration and tissue damage with potential as a surrogate end point in clinical trials. METHODS: A total of 121 volunteers aged ≥35 years with cardiovascular risk factors and MRI-confirmed WMLs were randomized to receive 200 mg mixed tocotrienols or placebo twice a day for 2 years. The WML volumes were measured from MRI images taken at baseline, 1 year, and 2 years using a validated software and were compared. Fasting blood samples were collected for full blood chemistry investigation. RESULTS: According to per-protocol (88 volunteers) and intention-to-treat (121 volunteers) analyses, the mean WML volume of the placebo group increased after 2 years, whereas that of the tocotrienol-supplemented group remained essentially unchanged. The mean WML volume change between the 2 groups was not significantly different (P=0.150) at the end of 1 year but was significant at the end of 2 years for both per-protocol and intention-to-treat analyses (P=0.019 and P=0.018). No significant difference was observed in the blood chemistry parameters between the 2 groups. CONCLUSIONS: Mixed tocotrienols were found to attenuate the progression of WMLs. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00753532.


Subject(s)
Leukoencephalopathies/drug therapy , Tocotrienols/pharmacology , Vitamins/pharmacology , Adult , Female , Humans , Leukoencephalopathies/blood , Leukoencephalopathies/pathology , Magnetic Resonance Imaging , Malaysia , Male , Middle Aged , Palm Oil , Plant Oils/administration & dosage , Plant Oils/adverse effects , Plant Oils/pharmacology , Tocotrienols/administration & dosage , Tocotrienols/adverse effects , Treatment Outcome , Vitamins/administration & dosage , Vitamins/adverse effects
3.
Nutr J ; 12(1): 166, 2013 Dec 27.
Article in English | MEDLINE | ID: mdl-24373555

ABSTRACT

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the commonest liver disorders. Obesity, insulin resistance, lipid peroxidation and oxidative stress have been identified amongst the possible hits leading to the onset and progression of this disease. Nutritional evaluation of NAFLD patients showed a lower-than-recommended intake of vitamin E. Vitamin E is a family of 8 isoforms, 4 tocopherols and 4 tocotrienols. Alpha-tocopherol has been widely investigated in liver diseases, whereas no previous clinical trial has investigated tocotrienols for NAFLD. Aim of the study was to determine the effects of mixed tocotrienols, in normalising the hepatic echogenic response in hypercholesterolaemic patients with ultrasound-proven NAFLD. METHODS: Eighty-seven untreated hypercholesterolaemic adults with ultrasound-proven NAFLD were enrolled and randomised into control group (n = 44) and tocotrienols group (n = 43). The treatment, either mixed tocotrienols 200 mg twice daily or placebo, had a 1-year duration.Normalisation of hepatic echogenic response, being the trial primary aim, was used in sample size calculations. The data were assessed according to intention to treat principle as primary outcome. Per protocol analysis was also carried out as secondary outcome measurement. RESULTS: Thirty and 34 participants concluded the study in the tocotrienols and placebo group respectively. Alpha-tocopherol levels were within the normal range for all subjects. As primary outcome, the normalisation of hepatic echogenic response was significantly higher for the tocotrienols treated group compared to the placebo group in the intention to treat analysis (P = 0.039; 95% CI = 0.896-6.488). As secondary objective, the per protocol assessment also showed significant rate of remission (P = 0.014; 95% CI = 1.117-9.456). Worsening of NAFLD grade was recorded in two patients in the placebo group, but none in the group treated with tocotrienols. No adverse events were reported for both groups. CONCLUSION: This is the first clinical trial that showed the hepatoprotective effects of mixed palm tocotrienols in hypercholesterolemic adults with NAFLD.


Subject(s)
Fatty Liver/drug therapy , Liver/drug effects , Tocotrienols/administration & dosage , alpha-Tocopherol/administration & dosage , Adult , Aged , Alanine Transaminase/blood , Apolipoproteins B/blood , Aspartate Aminotransferases/blood , C-Reactive Protein/metabolism , Cholesterol/blood , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Liver/diagnostic imaging , Liver/metabolism , Male , Middle Aged , Non-alcoholic Fatty Liver Disease , Nutrition Assessment , Prospective Studies , Risk Factors , Triglycerides/blood , Ultrasonography , gamma-Glutamyltransferase/blood
4.
AAPS PharmSciTech ; 14(3): 911-8, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23703233

ABSTRACT

Artemisinin, a poorly water-soluble antimalarial drug, presents a low and erratic bioavailability upon oral administration. The aim of this work was to study an agglomerated powder dosage form for oral administration of artemisinin based on the artemisinin/ß-cyclodextrin primary microparticles. These primary microparticles were prepared by spray-drying a water-methanol solution of artemisinin/ß-cyclodextrin. ß-Cyclodextrin in spray-dried microparticles increased artemisinin water apparent solubility approximately sixfold. The thermal analysis evidenced a reduction in the enthalpy value associated with drug melting, due to the decrease in drug crystallinity. The latter was also evidenced by powder X-ray diffraction analysis, while (13)C-NMR analysis indicated the partial complexation with ß-cyclodextrin. Agglomerates obtained by sieve vibration of spray-dried artemisinin/ß-cyclodextrin primary microparticles exhibited free flowing and close packing properties compared with the non-flowing microparticulate powder. The in vitro dissolution rate determination of artemisinin from the agglomerates showed that in 10 min about 70% of drug was released from the agglomerates, whereas less than 10% of artemisinin was dissolved from raw material powder. Oral administration of agglomerates in rats yielded higher artemisinin plasma levels compared to those of pure drug. In the case of the agglomerated powder, a 3.2-fold increase in drug fraction absorbed was obtained.


Subject(s)
Artemisinins/administration & dosage , beta-Cyclodextrins/administration & dosage , Administration, Oral , Artemisinins/pharmacokinetics , Biological Availability , Calorimetry, Differential Scanning , Dosage Forms , Magnetic Resonance Spectroscopy , Microscopy, Electron, Scanning , Solubility , Spectroscopy, Fourier Transform Infrared , Thermodynamics , beta-Cyclodextrins/pharmacokinetics
5.
Article in English | MEDLINE | ID: mdl-21073069

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and a frequent finding on ultrasound examination. NAFLD is considered as the liver component of metabolic syndrome and is linked to accelerated atherosclerosis and cardiovascular disease. No data from systematic studies regarding the prevalence of NAFLD are available for the Malaysian population. One hundred eighty untreated hypercholesterolemic volunteers underwent blood and ultrasound examinations to evaluate their livers. NAFLD was diagnosed in 102 subjects (56.7%) with similar prevalences between sexes. Of the 102 positive subjects 82 (80.4%) were graded as mild, 17 (16.7%) as moderate and 3 (2.9%) as severe fatty liver cases. Elevated fasting plasma glucose (FPG) levels were found in 13 of 180 subjects (7.2%), while elevated AST and ALT levels were seen in 30 (16.7%) and 22 (12.2%) of the180 subjects, respectively.


Subject(s)
Hypercholesterolemia/complications , Adult , Aged , Fatty Liver/complications , Fatty Liver/diagnostic imaging , Fatty Liver/epidemiology , Female , Humans , Hypercholesterolemia/epidemiology , Malaysia/epidemiology , Male , Middle Aged , Non-alcoholic Fatty Liver Disease , Prevalence , Ultrasonography
6.
J Pharm Pharmacol ; 61(4): 445-9, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19298690

ABSTRACT

OBJECTIVES: A liposome preparation that is amenable to receptor-mediated endocytosis has been developed to enhance the oral bioavailability of poorly absorbable peptidomimetic drugs by use of folic acid as the mediator of liposomal uptake. METHODS: Folic acid was physically coupled to the surface of the liposomes and cefotaxime was used as the model drug. In-vivo evaluation was carried out on eight Sprague-Dawley rats in a two-way crossover study to compare the oral bioavailability of cefotaxime loaded in folic acid-free liposomes and folic acid-coupled liposomes. Blood samples were collected from the tail vein and plasma cefotaxime levels were determined using an HPLC method. KEY FINDINGS: Enhanced oral bioavailability (AUC(0-infinity)) of cefotaxime was observed when administered via folic acid-coupled liposomes. The peak plasma concentration (C(max)) of cefotaxime was increased when administered via folic acid-coupled liposomes as compared with folic acid-free liposomes. At 90% confidence interval, the value for AUC(0-infinity) was 1.4-2-times higher and the value for C(max) was 1.2-1.8-times higher for the folic acid-coupled liposomes compared with folic acid-free liposomes. CONCLUSIONS: Folic acid could enhance the uptake of liposomally entrapped drug. It could be a useful candidate to supplement liposome delivery systems.


Subject(s)
Cefotaxime/administration & dosage , Drug Delivery Systems , Endocytosis/drug effects , Liposomes , Administration, Oral , Animals , Biological Availability , Cefotaxime/pharmacokinetics , Cross-Over Studies , Folic Acid/administration & dosage , Folic Acid/chemistry , Male , Random Allocation , Rats , Rats, Sprague-Dawley
7.
Drug Dev Ind Pharm ; 32(3): 335-45, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16556538

ABSTRACT

A liposome system was evaluated for oral delivery of a poorly bioavailable hydrophilic drug. The system was prepared from proliposome, which consisted of negatively charged phosphatidylcholine, whereas cefotaxime was chosen as the model drug. An in vivo study was carried out on nine rats according to a three-way crossover design to compare the oral bioavailability of cefotaxime from the liposomal formulation with that of an aqueous drug solution and a physical mixture of cefotaxime with blank liposomes. The results indicated that the extent of bioavailability of cefotaxime was increased approximately 2.7 and 2.3 times compared with that of the aqueous solution and the physical mixture, respectively. In a separate study, simultaneous determination of cefotaxime in intestinal lymph (collected from the mesenteric lymph duct) and in plasma (collected from the tail vein) revealed that its concentration was consistently higher in the lymph than in the plasma when administered via the liposomal formulation, whereas the reverse was observed with the aqueous solution. Thus, the results indicated that the liposomes system has the potential of increasing the oral bioavailability of poorly bioavailable hydrophilic drugs and also promote their lymphatic transport in the intestinal lymph.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Cefotaxime/pharmacokinetics , Lymphatic System/metabolism , Phosphatidylcholines/chemistry , Animals , Anti-Bacterial Agents/administration & dosage , Area Under Curve , Biological Availability , Cefotaxime/administration & dosage , Cross-Over Studies , Liposomes , Male , Particle Size , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...